1. A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis 
Flavio Vincenti, Fernando C. Fervenza, Kirk N. Campbell, Montserrat Diaz, Loreto Gesualdo, Peter Nelson, Manuel Praga, Jai Radhakrishnan, Lorenz Sellin, Ajay Singh, Denyse Thornley-Brown, Francisco Veríssimo Veronese, Beverly Accomando, Sara Engstrand, Steven Ledbetter, Julie Lin, John Neylan, James Tumlin 
Kidney International Reports 
Volume 2, Issue 5, Pages (September 2017)
DOI: /j.ekir
Copyright © 2017 International Society of Nephrology Terms and Conditions

2. Figure 1 Consolidated Standards of Reporting Trials (CONSORT) diagram.
Kidney International Reports 2017 2, DOI: ( /j.ekir )
Copyright © 2017 International Society of Nephrology Terms and Conditions

3. Figure 2
(a) Estimated mean percent change in urinary protein/creatinine ratio (Up/c) from baseline to day 112/visit 6 by treatment assignment. (b) Mean (± SE) percent change from baseline in estimated glomerular filtration rate (eGFR) over time by treatment assignment.
Kidney International Reports 2017 2, DOI: ( /j.ekir )
Copyright © 2017 International Society of Nephrology Terms and Conditions

4. Figure S1
Focal segmental glomerulosclerosis (FSGS) patients assigned to 1 mg/kg (n = 14).
Kidney International Reports 2017 2, DOI: ( /j.ekir )
Copyright © 2017 International Society of Nephrology Terms and Conditions

5. Figure S2
Focal segmental glomerulosclerosis (FSGS) patients assigned to placebo (n = 10).
Kidney International Reports 2017 2, DOI: ( /j.ekir )
Copyright © 2017 International Society of Nephrology Terms and Conditions

6. Figure S3
Focal segmental glomerulosclerosis (FSGS) patients assigned to 1 mg/kg with > 1 partial remission event (n = 6).
Kidney International Reports 2017 2, DOI: ( /j.ekir )
Copyright © 2017 International Society of Nephrology Terms and Conditions

7. Figure S4
Focal segmental glomerulosclerosis (FSGS) patients assigned to 4 mg/kg (n = 12; 3 treated with other immunosuppressant medications).
Kidney International Reports 2017 2, DOI: ( /j.ekir )
Copyright © 2017 International Society of Nephrology Terms and Conditions

8. Figure S5 Postinfusion fresolimumab serum concentrations (mean ± SE).
Kidney International Reports 2017 2, DOI: ( /j.ekir )
Copyright © 2017 International Society of Nephrology Terms and Conditions